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Reply
We appreciate that Dr. Puri and his colleagues have exhibited an
interest in our recent report (1) and have contributed their
comments. Because their comments bring up important points, we
would like to extend the discussion.
First, Puri et al. emphasize the superiority of the volumetric
measurements in intravascular imaging studies, compared with single-
frame analysis. Their assertion seems to be based mainly on a previous
intravascular ultrasound study that investigated the relationship be-
tween the change in plaque volume and cardiovascular risk factors (2).
lthough it may be true that for some studies, volumetric analysis is
arranted, this is not necessarily the case for our study. Before we
ndergo volumetric measurements, we first need to define the correct
easurements to make given the 3-dimensional structure. To choose
orresponding sites for comparison, we carefully coregistered the
ptical coherence tomographic (OCT) images using landmarks and
nalyzed the serial OCT frames. This procedure has been well
stablished in a variety of OCT and intravascular ultrasound studies
3) and therefore should provide valid data and results.
Second, a histology–OCT imaging comparison study by Kume
t al. (4) reported very high accuracy of OCT measurements for
ntimal plus medial area and intimal thickness. Considering that
edial area is calculated by subtracting the intimal area from
ntimal plus medial area, their results support the legitimacy of
edial area assessment by OCT imaging. We agree that medial
rea calculation should be standardized, as Puri et al. suggest.
Finally, regarding “catheter-induced spasm,” many previous spasm
tudies using coronary angiography have already reported luminal
arrowing even when asymptomatic (5). Because racial differences in
he incidence of spasm have been reported (6), we assume that some
octors in Western countries do not have enough clinical experience
ith this disease, which involves pathogenesis of a wide variety of
schemic heart diseases (7). Therefore, we would like to emphasize the
mportance of spasm in which the tunica media may play a key role.
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Antiarrhythmic Drug
Therapy in 2012
Time to Finally Open Our Eyes!
I read with interest the study by Saksena et al. (1) recently
published in the Journal. Analyzing data from the AFFIRM
(Atrial Fibrillation Follow-Up Investigation of Rhythm Manage-
ment) trial, the authors report that atrial fibrillation patients
treated with amiodarone have higher rates of death (noncardio-
vascular, in particular) and of cardiovascular hospitalization. An
adverse effect of amiodarone, especially among patients with heart
failure, had been previously observed in a subgroup analysis of the
SCD-HeFT (Sudden Cardiac Death in Heart Failure) trial (2), as
well as in retrospective analyses of the CIBIS-II (Cardiac Insuffi-
ciency Bisoprolol Study II) (3), COMET (Carvedilol or Meto-
prolol European Trial) (4), and VALIANT (VALsartan In Acute
myocardial iNfarcTion) (5) trials. Several mechanisms may be
invoked to explain these findings: iatrogenic tachy- and bradyar-
rhythmias (6), drug-induced left ventricular dysynchrony (7),
drug-drug interactions (with digoxin, for example), and extracar-
diac toxicity (thyroid, liver, lungs) (6).
A light at the end of the tunnel had been seen by many
cardiologists with the introduction in clinical practice of droneda-
rone, an iodine-free amiodarone derivate. Indeed, the ATHENA
(A Placebo-Controlled, Double-Blind, Parallel Arm Trial to
Assess the Efficacy of Dronedarone 400 mg bid for the Prevention
of Cardiovascular Hospitalization or Death from Any Cause in
Patients With Atrial Fibrillation/Atrial Flutter) trial showed a
reduction in death and hospitalization for cardiovascular causes in
patients with atrial fibrillation (8). In sharp contrast, a worrisome
increase in mortality associated with the use of dronedarone in the
setting of left ventricular systolic dysfunction was observed in the
ANDROMEDA (Antiarrhythmic Trial with Dronedarone in
Moderate to Severe congestive heart failure Evaluating Morbidity
Decrease) trial (9). More recently, the PALLAS (Permanent
Atrial fibriLLAtion outcome Study using Dronedarone on top of
